S. Lynch

发表

Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis

S. Ripa, C. Munera, R. Swanton, 2013, Expert opinion on drug safety.

Efficacy and Safety of Once‐Daily Extended‐Release (ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic Pain

J. Pergolizzi, K. Broglio, E. He, 2017, Pain practice : the official journal of World Institute of Pain.

Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain

R. Raffa, J. Pergolizzi, A. Yarlas, 2015, Postgraduate medicine.

A randomized, placebo-controlled study of the impact of the 7-day buprenorphine transdermal system on health-related quality of life in opioid-naïve patients with moderate-to-severe chronic low back pain.

R. Raffa, J. Pergolizzi, A. Yarlas, 2013, The journal of pain : official journal of the American Pain Society.

Long‐term effectiveness and safety of once‐daily, single‐entity, extended‐release hydrocodone in patients of ≥75 years of age with moderate to severe nonmalignant and nonneuropathic pain

J. Pergolizzi, K. Broglio, E. He, 2017, Geriatric nursing.

Long-term safety and effectiveness of once-daily, single-entity, extended-release hydrocodone over 76 weeks of an open-label study in patients with chronic noncancer and nonneuropathic pain

S. Ripa, E. He, S. Lynch, 2016, Postgraduate medicine.

Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain

A. Yarlas, M. Brennan, S. Ripa, 2013, Expert opinion on pharmacotherapy.

Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.

S. Ripa, A. Shoup, J. Kutz, 2017, Pain physician.

ELENBECESTAT, E2609, A BACE INHIBITOR: RESULTS FROM A PHASE-2 STUDY IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT AND MILD-TO-MODERATE DEMENTIA DUE TO ALZHEIMER'S DISEASE

B. Albala, J. Luthman, J. Kaplow, 2018, Alzheimer's & Dementia.

Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate‐to‐Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials

R. Raffa, J. Pergolizzi, A. Yarlas, 2016, Pain practice : the official journal of World Institute of Pain.

A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression

R. Raffa, J. Pergolizzi, A. Yarlas, 2016, Pain practice : the official journal of World Institute of Pain.

A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain

S. Ripa, E. He, W. Wen, 2015, Expert opinion on pharmacotherapy.

Long-term effectiveness and safety of once-daily, single-entity, extended-release hydrocodone in patients of ≥75 years of age with moderate to severe nonmalignant and nonneuropathic pain.

J. Pergolizzi, K. Broglio, E. He, 2017, Geriatric nursing.